

Oral Anticoagulants							
Drug	Mechanism of Action	Half-life	Indication	Dose	Monitoring	Reversal	TEG Effect
Warfarin (Coumadin)	Blocks the regeneration of Vitamin K epoxide, inhibiting synthesis of vitamin K-dependent clotting factors II, VII, IX and X, and anticoagulant proteins C and S	20-60 hr	AFib, DVT, PE, Prosthetic valve embolism prophylaxis	Adjusted to reach goal INR INR 1.5-3.5	PT/INR	WVUH Adult Anticoagulation Reversal Guidelines	Insensitive to warfarin effect Possible Extended R Time
Apixaban (Eliquis)	Factor Xa Inhibitor	12 hr	AFib, DVT, PE	DVT/PE: 10 mg BID x 7 days followed by 5 mg BID AFib: 5 mg BID		WVUH Adult Anticoagulation Reversal Guidelines	Extended R Time
Edoxaban (Savaysa)	Factor Xa Inhibitor	10-14 hr	AFib, DVT, PE	60 mg daily		WVUH Adult Anticoagulation Reversal Guidelines	Being studied Likely Extended R Time
Rivaroxaban (Xarelto)	Factor Xa Inhibitor	5-9 hr	AFib, DVT, PE	DVT/PE: 15 mg BID x 21 days followed by 20 mg daily AFib: 20 mg daily		WVUH Adult Anticoagulation Reversal Guidelines	Extended R Time
Dabigatran (Pradaxa)	Direct Thrombin Inhibitor	12-17 hr; longer in impaired renal function	AFib, DVT, PE	150 mg BID		WVUH Adult Anticoagulation Reversal Guidelines	Extended R Time